Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 407-419, 2009. First published January 23, 2009; 10.1373/clinchem.2008.118356
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2008.118356v1
55/3/407    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Contois, J. H.
Right arrow Articles by Warnick, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Contois, J. H.
Right arrow Articles by Warnick, G. R.
(Clinical Chemistry. 2009;55:407-419.)
© 2009 American Association for Clinical Chemistry, Inc.

Special Report

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

John H. Contois1,a,2, Joseph P. McConnell2, Amar A. Sethi3, Gyorgy Csako3, Sridevi Devaraj4, Daniel M. Hoefner5 and G. Russell Warnick6

1 Maine Standards Company, Windham, ME;2 Mayo Clinic, Rochester, MN;3 National Institutes of Health, Bethesda, MD;4 UC Davis Medical Center, Sacramento, CA;5 Marshfield Clinic, Marshfield, WI;6 Berkeley HeartLab Inc, Alameda, CA.

aAddress correspondence to this author at: Maine Standards Company LLC, 765 Roosevelt Trail, Windham, ME 04062. Fax 207-892-2266; e-mail jcontois{at}mainestandards.com.

Background: Low-density lipoprotein cholesterol (LDL-C) has been the cornerstone measurement for assessing cardiovascular risk for nearly 20 years.

Content: Recent data demonstrate that apolipoprotein B (apo B) is a better measure of circulating LDL particle number (LDL-P) concentration and is a more reliable indicator of risk than LDL-C, and there is growing support for the idea that addition of apo B measurement to the routine lipid panel for assessing and monitoring patients at risk for cardiovascular disease (CVD) would enhance patient management. In this report, we review the studies of apo B and LDL-P reported to date, discuss potential advantages of their measurement over that of LDL-C, and present information related to standardization.

Conclusions: In line with recently adopted Canadian guidelines, the addition of apo B represents a logical next step to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) and other guidelines in the US. Considering that it has taken years to educate physicians and patients regarding the use of LDL-C, changing perceptions and practices will not be easy. Thus, it appears prudent to consider using apo B along with LDL-C to assess LDL-related risk for an interim period until the superiority of apo B is generally recognized.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
D. C. Chan, G. Lambert, P. H. R. Barrett, K.-A. Rye, E. M.M. Ooi, and G. F. Watts
Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
Clin. Chem., November 1, 2009; 55(11): 2049 - 2052.
[Abstract] [Full Text] [PDF]

Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
M. L. Mestek
Physical Activity, Blood Lipids, and Lipoproteins
American Journal of Lifestyle Medicine, July 1, 2009; 3(4): 279 - 283.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.